Table 1.
Some recent clinical trials related to SL (https://clinicaltrials.gov/ct2/home). All of the listed agents are inhibitors
| Agent | Target gene | Mutate/overexpressed gene | Cancer type | Phase and ClinicalTrials.gov identifier | First posted |
|---|---|---|---|---|---|
| Olaparib | PARP | BRCA1/2 | Platinum sensitive relapsed ovarian cancer and metastatic breast cancer | IV, NCT04330040 | 1 April 2020 |
| Niraparib | Advanced pancreatic adenocarcinoma | II, NCT03601923 | 26 July 2018 | ||
| Rucaparib | Metastatic and recurrent endometrial cancer | II, NCT03617679 | 6 August 2018 | ||
| Talazoparib | Leukemia | I, NCT03974217 | 4 June 2019 | ||
| AZD6738 | ATR | TP53 | Recurrent, persistent or progressive myelodysplastic syndrome (MDS) or chronic myelomonocytic leukemia | I, NCT03770429 | 10 December 2018 |
| BAY1895344 | ATR | ATM | Advanced solid tumors and lymphomas (ATM loss and/or ATM deleterious mutations will be included) | I, NCT03188965 | 16 June 2017 |
| SRA737 | CHK1 | CCNE1, TP53, BRCA1, BRCA2, MYC, RAD50 | Advanced solid tumors or Non-Hodgkin’s Lymphoma | I and II, NCT02797964 | 14 June 2016 |
| Prexasertib (LY2606368) | BRCA | BRCA1/2 mutation associated breast or ovarian cancer, triple-negative breast cancer, and high grade serous ovarian cancer | II, NCT02203513 | 30 June 2014 | |
| MYC, CCNE1, Rb, FBXW7, BRCA1, BRCA2, PALB2, RAD51C, RAD51D, ATR, ATM, CHK2 | Advanced solid tumors | II, NCT02873975 | 22 August 2016 | ||
| Adavosertib (AZD1775) | WEE1 | TP53 | Uterine Serous Carcinoma | II, NCT04590248 | 19 October 2020 |
| SETD2 | Advanced/metastatic solid tumors | II, NCT03284385 | 15 September 2017 | ||
| BRCA | Advanced refractory cancers/lymphomas/multiple myeloma | II, NCT04439227 | 19 June 2020 | ||
| CYC140 | PLK1 | KRAS | Advanced leukemias or Myelodysplastic syndromes | I, NCT03884829 | 21 March 2019 |
| BI 6727 | Advanced, nonresectable and/or metastatic solid tumor | I, NCT01145885 | 17 June 2010 | ||
| GSK461364 | Advanced solid tumor or Non-Hodgkin’s lymphoma that has relapsed or is refractory to standard therapies | I, NCT00536835 | 28 September 2007 | ||
| Sotorasib (AMG 510) | CD274/PD-L1 | Stage IV non-small cell lung cancer | II, NCT04933695 | 22 June 2021 | |
| AZD2014 | 4EBP1 | MYC | High-risk prostate cancer | I, NCT02064608 | 17 February 2014 |
| CC-115 | Advanced solid tumors, and hematologic malignancies | I, NCT01353625 | 13 May 2011 | ||
| AZD4573 | CDK9 | Relapsed/refractory hematological malignancies | I, NCT03263637 | 28 August 2017 | |
| TP-1287 | Advanced solid tumors Sarcoma | I, NCT03604783 | 27 July 2018 | ||
| P276-00 | Stage III (unresectable) or stage IV metastatic melanoma | II, NCT00835419 | 3 February 2009 |